May 17, 2020

The significance of WellStar's hospital acquisitions in Atlanta

WellStar Health System
Tenet Healthcare
Finance
Emory Healthcare
Admin
2 min
WellStar Health System's recent purchase of five Atlanta-area hospitals is valued at $661 million.
In an effort to expand its successful clinical care models and patient safety programs, WellStar Health System has come to terms on purchasing five Atla...

In an effort to expand its successful clinical care models and patient safety programs, WellStar Health System has come to terms on purchasing five Atlanta-area hospitals owned by Dallas-based Tenet Healthcare.

The deal is valued at $661 million, which includes a sale price of $575 million and around $86 million in debt.

RELATED TOPIC: GE Healthcare expands its healthcare consulting with purchase of Camden Group

Marrietta, Ga.-based WellStar will acquire North Fulton Hospital, Sylvan Grove Hospital, Atlanta Medical Center and its South Campus, Spalding Regional Hospital as well as Tenet’s complimentary physician practices in Atlanta. The facilities include a combined total of 1,192 licensed hospital beds with around 4,300 team members and a medical staff consisting of 1,390 physicians and advanced practice professionals.

“These strategic moves are a continuation of our mission to improve the health and well-being of our communities,” said WellStar president and CEO Candice Saunders. “WellStar will be better suited to address changes in the healthcare industry.”

RELATED TOPIC: Walgreens has purchased Rite Aid; but will it change the healthcare industry?

With a vision of delivering world-class healthcare, WellStar is the largest community not-for-profit health system in Georgia, serving over 1.4 million citizens in five counties. It is also a national leader in new innovative ways to execute healthcare delivery, and appeared on the recent list of FORTUNE’s 100 Best Companies to Work For.

Following the acquisition, WellStar will employ around 20,000 team members across 11 hospital campuses, as well as over 200 medical office locations and several outpatient facilities. The deal softens the blow from over the summer when WellStar was unable to finalize a deal to merge with Emory Healthcare.

RELATED TOPIC: Cerner to Purchase Health IT Siemens for $1.3 Billion

WellStar is seeking growth to expand the reach of its population health programs, which includes the launch of a clinically integrated network this year, according to Saunders. The system will extend its clinical and quality improvement programs to the newly acquired hospitals and clinics. 

Let's connect!   

Click here to read the latest edition of Healthcare Global magazine!

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

pharma
supplychain
peptides
medication
3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article